Theratechnologies Inc T.TH

RE:RE:RE:RE:HIV and multidrug resistance: update in 2021

[qwerty22]

Ok my memory wasn't that this was presented at such a prestigious conference so it's much more than anecdotal.

Hopefully they are pressing this side of the story because to me it has more validity than the LLV argument.

scarlet1967 wrote:

 

 

 

They had this survey not long ago.

 

• 60 percent said that their experience with Trogarzo ® was better than expected while 40 percent said it was about the same;
• 93 percent of respondents either found the IV infusion process very convenient or neutral (70 percent and 23 percent, respectively);
• 93 percent said they would likely recommend Trogarzo ® to another patient living with HIV;
• 87 percent expressed very high satisfaction with the experience of receiving an infusion and seeing a healthcare professional every two weeks; and,
• 80 percent were of the opinion that a touchpoint every two weeks was likely to support adherence to other HIV medications.

 

https://money.tmx.com/en/quote/THTX:US/news/8670339041357327

 

 

qwerty22 wrote:

 

"In a retrospective, multicenter study, carried out in France, using the Dat'Aids database, on 3 centers and 5,429 patients receiving a combination of ARVs for at least 6 months, 208 patients had a CV> 50 cp / mL. Of these 208 patients, 8.2% (n = 17) had resistance to 3 or 4 classes of ARVs. Nine patients were at a therapeutic standstill (≤ 2 ARVs remaining active among the 4 main NRTI, NNRTI, PI and INI classes), i.e. 4.3% of patients not controlled virologically and 0.17% of all patients on ARV treatment. Patients at a therapeutic standstill had a long history of ARV treatment and numerous episodes of virologic failure [6]."

You'd think that 0.17% of the total hiv+ population should be the minimum no. of people Trogarzo could pick up. Doesn't sound a lot but it's 1700 in a 1 million population. 

The poster that data comes from extrapolates their results to the whole of France to give a pop of 192 of these most vulnerable. Interesting they conclude things are mostly down to poor adherence. It's a shame thtx don't have some hard data showing Trogarzo increases adherence. I remember something along those lines but it seemed, from memory, anecdotal.

https://2jg4quetidw2blbbq2ixwziw-wpengine.netdna-ssl.com/wp-content/uploads/sites/2/posters/2020/1430_2_Raffi_00522.pdf

 

scarlet1967 wrote:

 

 

https://www.edimark.fr/Front/frontpost/getfiles/31182.pdf
 

scarlet1967 wrote:

 

 

"The goal of antiretroviral therapy (ARV), whatever the situation, should be to achieve and maintain a viral load (CV) <50 cp / mL, in order to optimize immune restoration, reduce the risk of selection of resistant viruses and decrease morbidity and mortality associated with HIV [1]. At present, the therapeutic combinations made available allow virological success in more than 90% of patients treated [2]. Unfortunately, some patients have uncontrolled CV. Situations of virological failure must be detected by regular checks of the VL, the causes must be identified and corrected early to restore virological success and prevent the accumulation of resistance mutations...."

 

 

 

 

 

They had this survey not long ago.

 

• 60 percent said that their experience with Trogarzo ® was better than expected while 40 percent said it was about the same;
• 93 percent of respondents either found the IV infusion process very convenient or neutral (70 percent and 23 percent, respectively);
• 93 percent said they would likely recommend Trogarzo ® to another patient living with HIV;
• 87 percent expressed very high satisfaction with the experience of receiving an infusion and seeing a healthcare professional every two weeks; and,
• 80 percent were of the opinion that a touchpoint every two weeks was likely to support adherence to other HIV medications.

 

https://money.tmx.com/en/quote/THTX:US/news/8670339041357327